Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPEOX vs Observation in MRD-positive Early-stage Colorectal Cancer
NCT05699746Phase 3Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin in colorectal cancer (CRC), sponsored by Zhejiang University. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05699746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699746.